Hear are the trends we spotted this week in women’s health, and as always, scroll for the top clicked stories.
🧬 Personalization is the theme of the moment. From a major JAMA trial showing risk-based mammogram schedules work as well as annual screening, to expanded FDA approval of a libido drug for postmenopausal women, women’s health is slowly moving away from one-size-fits-all care—at least in clinical research and regulation.
⚠️ Opposition matters. The Trump administration cavalierly claimed they’d simply burn a $10M birth control stockpile at the start of 2025, but this week we learned that stockpile is just sitting there. And now they’ll have to share with a court exactly why. It’s a long process, but it shows that voices in opposition matter.
📉 Better measurement is revealing uncomfortable truths. Objective blood-loss tools show postpartum hemorrhage is far more common than previously believed, echoing a broader pattern this year: when women’s health is actually measured accurately, the burden of disease looks much larger than we’ve been told.
Editor’s Note: This will be the last edition of the newsletter in 2025! Thank you for being a dedicated reader of the women’s health news that so often gets ignored. We will be back on January 6.